1. Introduction: Treating Cancer at the Level of Genes
Cancer is fundamentally a genetic disease: mutations in oncogenes, tumor-suppressor genes, and DNA-repair genes drive malignant behavior. Gene therapy in oncology attempts to intervene at that level — replacing a lost tumor suppressor, introducing a suicide gene, delivering an immunostimulatory gene, editing a driver mutation, or modifying immune cells ex vivo. The field has a long history of preclinical promise followed by clinical disappointment, punctuated by a few genuine successes. Its most consequential success is arguably not a «gene drug» at all but ex vivo gene-modified cell therapy — CAR-T cells. This article reviews the strategies, evidence, and limitations of cancer gene therapy.
2. Principal Strategies
| Strategy | Concept | Examples / status |
|---|---|---|
| Tumor-suppressor replacement | Restore a lost gene such as TP53 | Gendicine (adenoviral p53, approved in China); limited Western validation |
| Suicide gene therapy | Convert a prodrug into a cytotoxic agent in tumor cells | HSV-thymidine kinase + ganciclovir; cytosine deaminase; investigational |
| Immunostimulatory genes | Deliver cytokines or co-stimulatory molecules | Investigational |
| Oncolytic virotherapy | Replication-selective viruses lyse tumor cells | T-VEC approved for melanoma |
| Ex vivo gene-modified cells | Engineer immune cells (for example, CAR-T) | Approved products in leukemia/lymphoma/myeloma |
| Genome editing | CRISPR/Cas and related tools | Early-phase; mostly ex vivo editing |
2.1. Delivery Vehicles
Gene delivery uses viral vectors — adenovirus (non-integrating), retrovirus and lentivirus (integrating), adeno-associated virus (AAV), and herpes simplex virus — or non-viral methods such as liposomes, polymers, and electroporation. Each vector trades off efficiency, immunogenicity, capacity, and safety. A CNS-penetrating AAV vector is the basis of a recently approved gene therapy for a neurodegenerative disease, illustrating that vector technology is advancing across medicine, but tumor delivery remains a specific challenge.
3. Evidence and Milestones
3.1. The First Human Gene Therapy
The first approved human gene-transfer protocol, initiated in 1990 by Rosenberg and colleagues at the US National Institutes of Health, used a marker gene and then a tumor-necrosis-factor gene in tumor-infiltrating lymphocytes. These early trials established safety and feasibility but did not produce clear clinical benefit, setting a pattern for the field.
3.2. Tumor-Suppressor and Suicide Gene Approaches
Gendicine, an adenoviral p53 product, was approved in China in 2003 for head and neck cancer, and there are related products elsewhere, but Western regulatory agencies have not approved these based on the available data, and rigorous independent replication is limited. Suicide-gene strategies continue in trials with mixed results.
3.3. Oncolytic Virotherapy
T-VEC (talimogene laherparepvec), an engineered herpes simplex virus, was approved in 2015 for the local treatment of unresectable melanoma based on a randomized trial showing durable response benefit. Its introduction demonstrated that a genetically modified virus can be a viable licensed cancer therapy, though systemic efficacy in visceral disease remains limited.
3.4. Ex Vivo Gene-Modified Cell Therapy
The clearest clinical success of gene transfer in cancer is CAR-T therapy, in which a patient’s T cells are genetically engineered ex vivo to express a chimeric antigen receptor. CAR-T products are approved for B-cell leukemias, lymphomas, and multiple myeloma, with durable remissions in some patients. This is gene therapy applied to cells rather than delivered in vivo, and it remains its most mature application.
4. Major Limitations
- Delivery. Getting a gene into every tumor cell — or enough of them — is the field’s central problem, especially for solid tumors.
- Immunogenicity and safety. Viral vectors provoke immune responses; early integrating-vector trials were complicated by insertional oncogenesis (for example, leukemia in an X-linked severe combined immunodeficiency trial), which remains a cautionary lesson.
- Modest single-agent efficacy in most in vivo settings and difficulty targeting metastatic disease.
- Complexity and cost, particularly for ex vivo and editing-based products.
5. Early Research and Emerging Approaches
- In vivo CRISPR editing to disrupt oncogenes or restore tumor-suppressor function is extremely early; safety and delivery remain unresolved.
- Next-generation oncolytic viruses armed with cytokines or checkpoint inhibitors are in trials.
- Gene-edited allogeneic CAR-T cells aim to create off-the-shelf products.
6. Unresolved Questions and Speculative Directions
- Whether in vivo gene editing of tumors can ever be made safe, efficient, and selective enough for routine use is unknown and largely speculative. [Marked for verification.]
- How to convert local gene-therapy effects into control of metastatic disease is not yet solved.
7. Conclusion
Cancer gene therapy spans a wide range of strategies with very different evidence bases. Its clearest success is ex vivo gene-modified cell therapy (CAR-T), which is an approved treatment for several hematologic cancers. Oncolytic virotherapy has one licensed product for localized melanoma. Direct in vivo delivery of tumor-suppressor, suicide, or immunostimulatory genes remains largely investigational, limited by delivery, immunogenicity, and inconsistent efficacy. Genome editing is promising but very early. Claims of established benefit for direct cancer gene therapy should be treated with caution.
Sources and Key Research Centers
- National Cancer Institute — gene therapy and cellular therapy overviews.
- American Society of Gene & Cell Therapy (ASGCT) — the field’s professional and educational resources.
- First human gene-transfer protocol — Rosenberg SA et al., NIH, 1990; marker-gene and cytokine-gene trials in tumor-infiltrating lymphocytes. [Citation details to be verified.]
- Oncolytic virotherapy approval — T-VEC (talimogene laherparepvec) for melanoma (US FDA, 2015); pivotal randomized trial by Andtbacka and colleagues, Journal of Clinical Oncology, 2015. [Citation details to be verified.]
- Insertional oncogenesis cautionary case — Hacein-Bey-Abina S et al., New England Journal of Medicine, 2003 (X-linked SCID gene therapy). [Citation details to be verified.]
- ClinicalTrials.gov — ongoing trials of in vivo editing, armed oncolytic viruses, and allogeneic cell products (search terms: gene therapy cancer, in vivo CRISPR, oncolytic virus).
Note: citation identifiers are provided where available; readers should confirm bibliographic details against the publisher’s record. This article is an editorial scientific overview and is not a medical recommendation.